News | June 21, 2023
DGCI grants Emergency Use Authorisation to Gennova mRNA Covid booster vaccine
The booster vaccine can be administered safely to individuals who have received two doses of either Covaxin or Covishield
The booster vaccine can be administered safely to individuals who have received two doses of either Covaxin or Covishield
Convergent action on AMR identified as an important area of intervention
Panacea Biotec has announced the launch of its new range of high-quality pediatric food & nutritional products
The randomised, multi-centre, evaluator blinded, parallel group, active controlled Phase 3 trial is being led by Lanhzou Biotechnique Development
The new lab will enable the Group to accelerate its efforts in this area, building new competencies and capabilities, as well as strengthening Solvay’s ability to develop breakthroughs in biodegradable-by-design solutions.
Acuitas Therapeutics' LNP technology will support Bayer’s in vivo gene editing and protein replacement programs with the goal of specifically delivering RNA payloads to the desired target organ, the liver.
Debut Biotechnology has outstanding enzyme search and design technology and a bio-manufacturing platform (precision fermentation, cell-free synthesis) using those enzymes
Acquisition will further strengthen Lonza’s bioconjugates offering through the integration of the industry-leading proprietary Synaffix technology platform and R&D capabilities, including payload and site-specific linker technology
Two patents were filed during the quarter ended 31st March, 2023 and the cumulative filings till date are 3239
Agilent respectfully disagrees with the PTAB’s opinion of unpatentability in view of prior art previously considered by the USPTO during its primary examination
Subscribe To Our Newsletter & Stay Updated
